Zevra Therapeutics, Inc. (ZVRA) company profile
Close on Nov 18, 2026Market cap $551.08MP/E 10.0Yield –
About Zevra Therapeutics
Pharmaceutical Preparations, SIC 2834
Zevra Therapeutics, Inc. is a pharmaceutical company that develops and commercializes therapies for rare diseases. Its commercial products include MIPLYFFA for Niemann-Pick disease type C, OLPRUVA for urea cycle disorders, and AZSTARYS for attention deficit hyperactivity disorder, marketed through partners. The company also advances clinical candidates such as celiprolol for vascular Ehlers-Danlos syndrome and KP1077 for sleep disorders. Its products serve adult and pediatric patients with rare neurodegenerative, metabolic, and genetic conditions.
The company distributes products in the United States and provides MIPLYFFA in France, Germany, other European Union nations, and select global markets via an expanded access program. It is also seeking regulatory approval across the European Union. Partner agreements grant commercialization rights in European countries and Greater China. Furthermore, the company holds active patents across North America, Europe, Asia, and other territories. The excerpt does not mention the company's headquarters location.
Summary of the business section of Zevra Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Zevra Therapeutics, Inc.
- Headquarters
- Boston, MA
- Address
- 101 Federal Street 02110
- Phone
- (888) 958-1253
- Website
- zevra.com
- Employees
- 61, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Orlando, Florida
Stock & identifiers
- Ticker
- ZVRA
- Former tickers
- KMPH until Mar 7, 2023
- Exchange
- Nasdaq
- IPO date
- Apr 16, 2015
- Shares outstanding
- 59M, Jul 31, 2026
- Public float
- $454.80M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-16 reverse, Dec 28, 2020
- SEC CIK
- 1434647
- CUSIP
- 488445206
- ISIN
- US4884452065
- FIGI
- BBG0026ZG1F5
- Share class FIGI
- BBG0026ZG1G4
- LEI
- 254900CU6T74V18Y1W18
- EIN
- 20-5894398
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Neil F. McFarlane | President and CEO, Director | 417,225 |
| Rahsaan Thompson | Chief Legal & Compliance | 37,569 |
| Timothy J. Sangiovanni | SVP, Finance & Corp Controller | 29,590 |
| Justin A. Renz | CFO | – |
| Joshua Schafer | CCO | 62,278 |
| Adrian W. Quartel | Chief Medical Officer | 14,256 |
| Corey Michael Watton | Director | 1,800 |
| Thomas Anderson | Director | 20,000 |
| Tamara A. Favorito | Director | 3,894 |
| Alicia Secor | Director | – |
| Alvin Shih | Director | 20,000 |
| Douglas W. Calder | Director | – |
| John B. Bode | Director | 123,400 |
| Wendy L. Dixon | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $3.78M | $4.00M | $2.70M | – | $195 |
| FY2024 | $5.36M | $7.32M | $1.98M | – | $182 |
| FY2023 Christal M.Mickle | $1.67M | $2.21M | $2.04M | – | $143 |
| FY2023 Current CEO | $3.45M | $4.98M | $2.04M | – | $143 |
| FY2023 Former CEO1 | $3.59M | $4.39M | $2.04M | – | $143 |
| FY2023 Former CEO2 | $4.12M | $3.31M | $2.04M | – | $143 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Neil F. McFarlane President, Chief Executive Officer and Director | $729.17K | – | $874.13K | $1.75M | $418.95K | $11.55K | $3.78M | -29% |
| Rahsaan W. Thompson Chief Legal Officer, Secretary and Compliance Officer | $466.67K | $50.00K | $272.68K | $545.36K | $178.60K | $58.07K | $1.57M | – |
| R. LaDuane Clifton Former Chief Financial Officer and Treasurer | $477.31K | – | $1.26M | $1.12M | – | $966.97K | $3.82M | +164% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Apr 16, 2015
- Offer price
- $11.00
- Securities offered
- 5,090,909
- Gross proceeds
- $56.00M
- Exchange
- Nasdaq
- First trading day
- Apr 16, 2015
- First-day close
- $11.20+1.8%
- Lock-up ends (est.)
- Oct 13, 2015
“Our common stock has been approved for listing on The NASDAQ Global Market under the symbol “KMPH.” The initial public offering price is $11.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 61 full-time employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?